Insider Selling: Enfusion, Inc. (NYSE:ENFN) General Counsel Sells 1,695 Shares of Stock

Enfusion, Inc. (NYSE:ENFN - Get Free Report) General Counsel Matthew Campobasso sold 1,695 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $11.38, for a total value of $19,289.10. Following the sale, the general counsel now directly owns 70,946 shares of the company's stock, valued at approximately $807,365.48. This trade represents a 2.33 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Matthew Campobasso also recently made the following trade(s):

• On Monday, March 3rd, Matthew Campobasso sold 1,081 shares of Enfusion stock. The shares were sold at an average price of $11.48, for a total value of $12,409.88.
• On Tuesday, January 7th, Matthew Campobasso sold 976 shares of Enfusion stock. The shares were sold at an average price of $10.13, for a total value of $9,886.88.

Enfusion Price Performance

Shares of NYSE ENFN traded up $0.04 during mid-day trading on Tuesday, reaching $11.15. The company's stock had a trading volume of 780,007 shares, compared to its average volume of 1,156,687. Enfusion, Inc. has a 52 week low of $7.83 and a 52 week high of $11.80. The stock has a fifty day moving average of $10.99 and a two-hundred day moving average of $9.92. The firm has a market capitalization of $1.44 billion, a PE ratio of 278.69, a P/E/G ratio of 1.85 and a beta of 0.95.

Enfusion (NYSE:ENFN - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.02). Enfusion had a return on equity of 6.67% and a net margin of 1.70%. The company had revenue of $52.94 million during the quarter, compared to analysts' expectations of $53.98 million. Analysts anticipate that Enfusion, Inc. will post 0.06 EPS for the current fiscal year.

Remove Ads

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ENFN. Harbor Capital Advisors Inc. raised its stake in Enfusion by 12.4% during the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company's stock valued at $113,000 after purchasing an additional 1,315 shares in the last quarter. Versor Investments LP purchased a new stake in shares of Enfusion during the 3rd quarter valued at about $501,000. Impax Asset Management Group plc raised its position in shares of Enfusion by 25.4% during the 3rd quarter. Impax Asset Management Group plc now owns 676,948 shares of the company's stock valued at $6,424,000 after buying an additional 136,948 shares in the last quarter. Royce & Associates LP lifted its holdings in shares of Enfusion by 35.4% in the 3rd quarter. Royce & Associates LP now owns 99,715 shares of the company's stock valued at $946,000 after acquiring an additional 26,045 shares during the last quarter. Finally, Gladius Capital Management LP increased its stake in Enfusion by 160.5% during the third quarter. Gladius Capital Management LP now owns 69,694 shares of the company's stock worth $661,000 after acquiring an additional 42,939 shares during the last quarter. 81.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on ENFN shares. Piper Sandler boosted their price objective on shares of Enfusion from $10.00 to $11.50 and gave the company a "neutral" rating in a research report on Monday, December 23rd. William Blair reaffirmed a "market perform" rating on shares of Enfusion in a research note on Monday, January 13th. Finally, Stifel Nicolaus raised their price target on Enfusion from $11.00 to $13.00 and gave the company a "buy" rating in a report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, Enfusion presently has a consensus rating of "Hold" and a consensus target price of $11.13.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.